ArticleDiabetology & metabolic syndrome2025
Association between metabolic visceral fat score and left ventricular hypertrophy in individuals with type 2 diabetes.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07204782 (Elevated Cardiovascular Risk Scores With Diabetes Mellitus Type 2 and Their Association With Non-Invasive Visceral Adiposity Indices), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Elevated Cardiovascular Risk Scores With Diabetes Mellitus Type 2 and Their Association With Non-Invasive Visceral Adiposity Indices
Who cites it
2 citing papers in PubMed.
- Association analysis of metabolic score for visceral fat with cardiovascular disease: a prospective cohort study based on the China health and retirement longitudinal study.Cardiovascular diagnosis and therapy · 2026Article
- Neck Circumference and the Heart: Unveiling a New Anthropometric Marker for LVH Risk in Type 2 Diabetes-The TESEO Study.Diabetes/metabolism research and reviews · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundLeft ventricular hypertrophy (LVH), a hallmark of early-stage heart failure (HF), is a common complication in individuals with type 2 diabetes mellitus (T2DM). Metabolic Visceral Fat Score (METS-VF), a novel metric for estimating visceral adiposity, may provide valuable insights into LVH risk. This study explores the association between METS-VF and LVH in T2DM and compare its predictive performance to traditional abdominal obesity indices.
methodsThis cross-sectional study included 4,988 adults with T2DM. Participants were stratified into quartiles based on METS-VF. Logistic regression models assessed the association between METS-VF and LVH. Restricted cubic spline analyses evaluated nonlinear relationships, while stratified analyses explored subgroups effects. Receiver operating characteristic (ROC) curves compared the predictive performance of METS-VF with other indices.
resultsLVH prevalence increased across METS-VF quartiles (Quartile 1: 7.9%; Quartile 2: 13.0%; Quartile 3: 20.0%; Quartile 4: 31.0%; P < 0.001). Higher METS-VF was independently associated with LVH (OR: 9.79; 95% CI: 6.16-15.76; P < 0.001). A nonlinear relationship was observed between METS-VF and LVH, with a steeper risk increase above specific thresholds. Stratified analyses showed that the positive association between METS-VF and LVH was consistent. METS-VF outperformed traditional indices in predicting LVH (AUC: 0.68; 95% CI: 0.66-0.70).
conclusionsMETS-VF is strongly associated with LVH in T2DM, demonstrating superior predictive performance compared to traditional indices. METS-VF is a practical, cost-effective tool for early cardiac risk stratification, facilitating timely interventions to mitigate HF risk in T2DM populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.